Drug Profile
Research programme: protein modulators - PTC Therapeutics
Alternative Names: DBMD-Utrophin; DMD Exon-51; Project Catalyst; SERCA2a protein stimulants - PTC TherapeuticsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator PTC Therapeutics
- Class Small molecules
- Mechanism of Action Dystrophin expression modulators; Insulin-like growth factor I stimulants; Myostatin inhibitors; Sarcoplasmic reticulum calcium-transporting ATPase stimulants; Utrophin activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Duchenne muscular dystrophy
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Duchenne muscular dystrophy in USA (PO)
- 28 Jan 2014 Early research for Duchenne muscular dystrophy is ongoing in USA (PO)
- 15 Dec 2011 This programme is still in active development